Prelude Therapeutics Inc (OQ:PRLD)

Business Focus: Biotechnology & Medical Research

May 07, 2024 07:01 am ET
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the first quarter ended March 31, 2024 and provided an update on recent clinical development pipeline and other...
Apr 09, 2024 04:35 pm ET
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting for its highly selective...
Mar 05, 2024 04:45 pm ET
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9...
Feb 29, 2024 04:05 pm ET
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024. On Wednesday,...
Feb 15, 2024 04:05 pm ET
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.    "In 2023, we prioritized and...
Dec 11, 2023 09:34 am ET
Prelude Therapeutics Announces $25 Million Private Placement
Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million...
Nov 11, 2023 07:48 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Incorporated (NASDAQ: PRLD) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Prelude Therapeutics Incorporated (NASDAQ: PRLD) (“Prelude”) on behalf of the company’s investors. Since April 2023, shares of Prelude’s common stock have declined in value from a trading price of...
Nov 04, 2023 07:45 am ET
Investor Alert: Abbott Cooper PLLC Investigates Prelude Therapeutics Incorporated; Urges Prelude Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC is investigating Prelude Therapeutics Incorporated (NASDAQ: PRLD) (“Prelude” or the “Company”) on behalf of the Company’s investors. The objective of this investigation is to determine whether Prelude’s board of directors (the...
Nov 01, 2023 04:10 pm ET
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today provides strategic pipeline updates and reports third quarter financial results. Recent clinical progress and strategic prioritization...
Nov 01, 2023 04:05 pm ET
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer. The collaboration combines Prelude’s expertise in targeted protein degradation, medicinal chemistry, and clinic
Nov 01, 2023 04:05 pm ET
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with...
Oct 14, 2023 12:30 pm ET
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 
Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer...
Oct 02, 2023 10:30 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Prelude Therapeutics Inc. (NASDAQ: PRLD) (“Prelude”) on behalf of the company’s investors. Since April 2023, shares of Prelude’s common stock have declined in value from a trading price of over...
Aug 29, 2023 08:30 am ET
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: Wells Fargo 18th...
Aug 03, 2023 08:00 am ET
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. Kris Vaddi, Ph.D., Chief Executive Officer...
May 31, 2023 08:30 am ET
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Jefferies Healthcare Conference, taking place in New York City, June 7 to 9, 2023....
May 18, 2023 07:00 am ET
Prelude Therapeutics Announces Pricing of Public Offering
Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and 1,448,222...
May 17, 2023 04:08 pm ET
Prelude Therapeutics Announces Launch of Proposed Public Offering
Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, in...
May 08, 2023 08:30 am ET
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent clinical and development pipeline progress....
Apr 27, 2023 08:30 am ET
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: H. C. Wainwright...
Apr 11, 2023 08:30 am ET
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight abstracts being presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking...
Mar 15, 2023 08:30 am ET
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update.    “We made considerable progress...
Mar 15, 2023 08:00 am ET
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in...
Mar 01, 2023 08:30 am ET
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023. On March 16, at...
Feb 09, 2023 09:05 am ET
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February. On Tuesday, February 14, at 8:40...
Nov 14, 2022 08:00 am ET
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent clinical and development...
Oct 18, 2022 08:00 am ET
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration, (FDA) cleared the company to proceed with a Phase 1 study under its Investigational...
Sep 06, 2022 08:00 am ET
Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City. On Monday,...
Aug 09, 2022 08:00 am ET
Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent clinical and development pipeline...
May 10, 2022 08:00 am ET
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update
Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development...
Mar 16, 2022 07:30 am ET
Prelude Therapeutics Reports Full Year 2021 Financial Results
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2021. “With Prelude’s core competencies in cancer biology and medicinal...
Mar 11, 2022 08:00 am ET
Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the Barclays 2022 Global Healthcare Conference in Miami, FL...
Mar 09, 2022 08:05 am ET
Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today provided a clinical update on its diverse and growing pipeline and announced that new preclinical data have been accepted for presentation at the upcoming...
Mar 09, 2022 08:00 am ET
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer
Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announced that Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4,...
Feb 11, 2022 07:00 am ET
Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday,...
Jan 04, 2022 07:00 am ET
Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13,...
Dec 21, 2021 08:31 am ET
Thinking about buying stock in Prelude Therapeutics, Miniso Group, Galera Therapeutics, Spruce Biosciences, or Purple Innovation?
NEW YORK, Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRLD, MNSO, GRTX, SPRB, and PRPL.
Nov 23, 2021 07:00 am ET
Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking...
Nov 12, 2021 08:00 am ET
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its financial results for the third quarter ended September 30, 2021 and provided an update on recent clinical and development pipeline progress....
Nov 08, 2021 09:00 am ET
Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its precision oncology...
Oct 19, 2021 08:40 am ET
Thinking about buying stock in Energous Corp, Entasis Therapeutics, Prelude Therapeutics, Biomerica, or Rockley Photonics?
NEW YORK, Oct. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WATT, ETTX, PRLD, BMRA, and RKLY.
Oct 07, 2021 09:00 am ET
Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of data from multiple pipeline programs, including the dose escalation portions of the Company’s ongoing Phase 1 trials of lead...
Sep 02, 2021 07:00 am ET
Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: Morgan Stanley 19th Annual Global Healthcare...
Aug 12, 2021 07:30 am ET
Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent clinical and development pipeline progress....
Jul 19, 2021 07:00 am ET
Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its Board of Directors. Mr. Babler brings to Prelude over 25 years of pharmaceutical and biotech experience,...
Jun 02, 2021 07:00 am ET
Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: 42nd Annual Goldman Sachs Global Healthcare...
May 11, 2021 07:30 am ET
Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent clinical and development pipeline progress....
May 05, 2021 07:00 am ET
Prelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference
Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the BofA Securities 2021 Virtual Health...
Mar 16, 2021 08:00 am ET
Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update
Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its financial results for the fourth quarter and full year ended December 31, 2020 and provided an update...
Mar 03, 2021 07:00 am ET
Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences
Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences:...
Jan 11, 2021 06:20 pm ET
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 shares...
Jan 07, 2021 12:12 am ET
Prelude Therapeutics Announces Pricing of Upsized Public Offering
Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its upsized public offering of 2,208,334 shares of its...
Jan 04, 2021 04:16 pm ET
Prelude Therapeutics Announces Launch of Proposed Public Offering
Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its common stock pursuant to a registration...
Nov 10, 2020 07:30 am ET
Prelude Therapeutics Announces Third Quarter 2020 Financial Results
Prelude Therapeutics Incorporated (“Prelude”, “the Company”, “we”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its financial results for the third quarter ended September 30, 2020 and provided an update on recent...
Sep 30, 2020 07:00 am ET
Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has been dosed in its first-in-human Phase 1 open-label, multicenter, dose-escalation study of PRT1419 in patients...
Sep 29, 2020 04:05 pm ET
Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public offering of 9,573,750 shares of common stock, including the full exercise of the underwriters’ option...
Sep 24, 2020 08:50 pm ET
Prelude Therapeutics Announces Pricing of Initial Public Offering
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share. The...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.